razoxane has been researched along with Cardiac Diseases in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (8.33) | 18.7374 |
| 1990's | 33 (45.83) | 18.2507 |
| 2000's | 21 (29.17) | 29.6817 |
| 2010's | 12 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamcová, M; Geršl, V; Hroch, M; Jirkovský, E; Lenčová-Popelová, O; Mazurová, Y; Mičuda, S; Šimůnek, T; Štěrba, M; Vávrová, J | 1 |
| Jones, RL | 1 |
| Belhani, D; Bui-Xuan, B; Descotes, J; Fanton, L; Manati, W; Tabib, A; Timour, Q; Vaillant, F | 1 |
| Adamcová, M; Gersl, V; Guncová, I; Hasková, P; Hroch, M; Mazurová, Y; Nachtigal, P; Popelová, O; Simůnek, T; Sterba, M | 1 |
| Herman, EH; Honchel, R; Knapton, AD; Lipshultz, SE; Retief, J; Rosenzweig, BA; Sistare, FD; Thompson, KL; Zhang, J | 1 |
| Gallegos-Castorena, S; Gonzalez-Ramella, O; Sánchez-Medina, J | 1 |
| Beijnen, JH; Goey, AK; Huitema, AD; Schellens, JH | 1 |
| Anderson, P; Chandra, J; Fulbright, JM; Huh, W | 1 |
| Dervisis, NG; FitzPatrick, WM; Kitchell, BE | 1 |
| McBride, D | 1 |
| Caron, HN; Dickinson, HO; Kremer, LC; van Dalen, EC | 1 |
| Agee, S; Estis, J; Hasinoff, B; Herman, EH; Knapton, A; Lipshultz, S; Lu, QA; Rosen, E; Rosenzweig, B; Thompson, K; Todd, JA; Zhang, J | 1 |
| Che, F; Liu, Y; Xu, C | 1 |
| Doroshow, JH | 1 |
| Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL | 1 |
| Ostański, M; Sońta-Jakimczyk, D | 1 |
| Alpert, L; Bernier, M; Chalifour, LE; Dostanic, S; Héon, S; Kirby, GM; Servant, N; Wang, C | 1 |
| Komagata, H; Sakai, H | 1 |
| Chitambar, CR; Joseph, J; Kalivendi, SV; Kalyanaraman, B; Konorev, E; Kotamraju, S | 1 |
| Gershanovich, ML | 2 |
| Arsovski, O; Debourdeau, P; Gligorov, J; Lotz, JP | 1 |
| Campos, O; Macedo, CR; Moisés, VA; Paiva, MG; Petrilli, AS; Tanaka, C | 1 |
| Charlier, H; Cusack, BJ; Gambliel, H; Hadjokas, N; Musser, B; Olson, RD; Shadle, SE | 1 |
| Chauvenet, A; Constine, LS; De Alarcon, PA; Friedman, D; London, WB; Mendenhall, NP; Schwartz, CL; Sposto, R; Tebbi, CK; Villaluna, D | 1 |
| Caron, HN; Kremer, LC; van Dalen, EC | 1 |
| Alvarez, JA; Barry, E; Lipshultz, SE; Miller, TL; Scully, RE | 1 |
| Hasinoff, BB; Herman, EH | 1 |
| Jensen, PB; Langer, SW; Sehested, M | 1 |
| Azarova, AM; Ban, Y; Kerrigan, JE; Lin, CP; Liu, LF; Lyu, YL; Tsai, YC | 1 |
| Hochster, H; Speyer, J; Wasserheit, C | 1 |
| Armand, JP; de Forni, M | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 1 |
| Bu'Lock, FA; Gabriel, HM; Martin, RP; Mott, MG; Oakhill, A | 1 |
| Catimel, G; Clavel, M; Merrouche, Y | 1 |
| Alberts, DS; Dawson, BV; Dorr, RT; Hendrix, M; Shipp, NG | 1 |
| Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Lipshultz, SE | 1 |
| Hellmann, K | 3 |
| Besse, P; Bonoron-Adèle, S; Gouverneur, G; Pouna, P; Robert, J; Tariosse, L | 1 |
| Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J | 1 |
| Betcher, DL; O'Marcaigh, AS | 1 |
| Grossmann, V; Kvĕtina, J; Safárová, M; Svoboda, Z | 1 |
| Blum, RH | 1 |
| Semiglazov, VF | 1 |
| Phillips, KA; Tannock, IF | 1 |
| Swain, SM | 1 |
| Lopez, M; Vici, P | 1 |
| Lemez, P; Maresová, J | 1 |
| Wexler, LH | 1 |
| Doroshow, JH; Synold, TW; Tetef, ML | 1 |
| Spencer, CM; Wiseman, LR | 1 |
| Mazzarello, GP; Morra, L | 1 |
| Chadwick, DP; Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Chakrabarti, KB; Hopewell, JW; Plowman, PN; Wilding, D | 1 |
| Green, MR; Herndon, JE; Kindler, HL; Kosty, MP; Vogelzang, NJ | 1 |
| Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M | 1 |
| Ardalan, B; Bier, C; Herman, E; Krop, S; Waravdekar, V | 1 |
| Blum, RH; Green, M; Hochster, H; Liebes, L; Meyers, M; Oratz, R; Speyer, JL; Wadler, S; Wernz, JC | 1 |
| Carlson, RW | 1 |
| Creighton, AM; Hopewell, JW; Jaenke, RS; Wilding, D; Yeung, TK | 1 |
| Forbes, JF | 1 |
| Curran, CF; Narang, PK; Reynolds, RD | 1 |
| Baba, H; Bull, JM; Newman, RA; Ohno, S; Siddik, ZH; Stephens, LC; Strebel, FR | 1 |
| Cova, D; Favalli, L; Galimberti, M; Lanza, E; Monti, E; Poggi, P; Rozza-Dionigi, A; Villani, F | 1 |
| el-Hage, A; Ferrans, VJ; Herman, EH | 1 |
| Ferrans, VJ; Herman, EH | 1 |
| Ferrans, VJ; Hamlin, RL; Herman, EH; Young, RS | 1 |
| Bhat, HB; Ferrans, VJ; Herman, EH; Witiak, DT | 1 |
28 review(s) available for razoxane and Cardiac Diseases
| Article | Year |
|---|---|
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Topics: Aged; Animals; Anthracyclines; Antibiotics, Antineoplastic; Bone Marrow; Cardiotonic Agents; Chelating Agents; Child; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heart Diseases; Humans; Neoplasms; Razoxane | 2008 |
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Topics: Anthracyclines; Cardiovascular Agents; Heart Diseases; Heart Failure; Humans; Randomized Controlled Trials as Topic; Razoxane | 2010 |
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
Topics: Adolescent; Adult; Anthracyclines; Child; Delayed-Action Preparations; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Carriers; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Heart; Heart Diseases; Heart Failure; Humans; Iron Chelating Agents; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Razoxane; Risk Factors; Treatment Outcome | 2010 |
Cardioprotective interventions for cancer patients receiving anthracyclines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cytoprotection; Heart Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane | 2011 |
Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Extravasation of Diagnostic and Therapeutic Materials; Heart Diseases; Humans; Injections, Intravenous; Iron; Razoxane; Reactive Oxygen Species | 2012 |
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antioxidants; Carbazoles; Cardiolipins; Cardiotonic Agents; Carvedilol; Doxorubicin; Erythropoietin; Heart; Heart Diseases; Humans; Lipid Peroxidation; Liposomes; Neoplasms; Piperazines; Propanolamines; Purines; Razoxane; Risk Factors; Sildenafil Citrate; Sulfones; Survivors; Ventricular Dysfunction, Left | 2012 |
[Chemotherapy-induced cardiac toxicity and management].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography; Heart; Heart Diseases; Humans; Monitoring, Physiologic; Neoplasms; Razoxane | 2003 |
Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis.
Topics: Aconitate Hydratase; Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Caspases; Cells, Cultured; Chelating Agents; Cytochromes c; Doxorubicin; Endothelium; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Regulatory Protein 1; Iron-Regulatory Proteins; Mitochondria; Muscle Cells; Oxidants; Oxidation-Reduction; Oxidative Stress; Razoxane; Reactive Oxygen Species; Receptors, Transferrin; Response Elements; RNA, Messenger; Signal Transduction; Superoxides; Up-Regulation | 2004 |
[Cardiac prevention: the oncologic point of view].
Topics: Age Factors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Heart; Heart Diseases; Humans; Liposomes; Paclitaxel; Razoxane; Risk Factors; Trastuzumab | 2004 |
Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
Topics: Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Child; Coenzymes; Heart Diseases; Humans; Randomized Controlled Trials as Topic; Razoxane; Risk Factors; Ubiquinone | 2007 |
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Drug Interactions; Drug Monitoring; Heart; Heart Diseases; Humans; Neoplasms; Razoxane; Risk Factors | 2007 |
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Topics: Animals; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Enzyme Inhibitors; Heart Diseases; Humans; Neoplasms; Prodrugs; Razoxane; Topoisomerase II Inhibitors | 2007 |
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heart Diseases; Humans; Mice; Razoxane | 2007 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors | 1995 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane | 1994 |
Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Kidney Diseases; Neoplasms; Neutropenia; Razoxane | 1993 |
Dexrazoxane (ICRF-187): a cardioprotective agent during anthracycline chemotherapy.
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart Diseases; Humans; Razoxane | 1997 |
Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Heart Diseases; Humans; Iron; Myocardium; Razoxane; Safety; Treatment Outcome | 1997 |
[Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart; Heart Diseases; Humans; Razoxane | 1997 |
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Topics: Amifostine; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Leukopoiesis; Randomized Controlled Trials as Topic; Razoxane; Research Design; Thrombocytopenia | 1998 |
Overview and historical development of dexrazoxane.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane | 1998 |
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Razoxane | 1998 |
European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Heart Diseases; Humans; Razoxane | 1998 |
Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane | 1998 |
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Heart Diseases; Humans; Neoplasms; Razoxane | 1998 |
[Anthracyclines and the heart].
Topics: Anthracyclines; Cardiovascular Agents; Heart; Heart Diseases; Humans; Razoxane | 1998 |
Long-term effects of adjuvant chemotherapy in breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Heart; Heart Diseases; Hodgkin Disease; Humans; Leukemia; Lymphatic Metastasis; Menopause; Menstruation; Monitoring, Physiologic; Neoplasms, Second Primary; Ovary; Razoxane | 1992 |
Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.
Topics: Animals; Doxorubicin; Heart Diseases; Humans; Razoxane | 1991 |
10 trial(s) available for razoxane and Cardiac Diseases
| Article | Year |
|---|---|
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Blood Pressure; Cardiotonic Agents; Child; Dobutamine; Doxorubicin; Drug Antagonism; Echocardiography, Stress; Female; Heart Diseases; Heart Rate; Humans; Male; Osteosarcoma; Razoxane; Ventricular Function, Left | 2005 |
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chelating Agents; Cohort Studies; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid; Lung Diseases; Male; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Osteosarcoma; Razoxane; Risk Assessment; Risk Factors; Thyroid Neoplasms; Time Factors; Topoisomerase II Inhibitors | 2007 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Heart; Heart Diseases; Humans; Neoplasms; Pilot Projects; Razoxane | 1993 |
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Razoxane | 1996 |
Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Daunorubicin; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Razoxane | 1998 |
Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Doxorubicin; Heart Diseases; Humans; Razoxane; Topoisomerase II Inhibitors | 1998 |
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Heart Diseases; Humans; Male; Mesothelioma; Middle Aged; Neutropenia; Razoxane; Thrombocytopenia | 2001 |
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Doxorubicin; Economics, Pharmaceutical; Female; Fluorouracil; Health Care Costs; Heart; Heart Diseases; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Razoxane; Sensitivity and Specificity | 1996 |
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Doxorubicin; Heart Diseases; Humans; Razoxane | 1992 |
34 other study(ies) available for razoxane and Cardiac Diseases
| Article | Year |
|---|---|
Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Citrate (si)-Synthase; Daunorubicin; Heart Diseases; Male; NF-E2-Related Factor 2; Oxidative Stress; Rabbits; Razoxane; Troponin T; Ventricular Function, Left | 2013 |
Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine.
Topics: Animals; Cardiotonic Agents; Female; Heart Diseases; Male; Rabbits; Razoxane; Testosterone; Trimetazidine | 2009 |
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
Topics: Animals; Anthracyclines; Apoptosis; Cardiotonic Agents; Cardiotoxins; Heart Diseases; Male; Myocytes, Cardiac; Rabbits; Razoxane | 2009 |
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Gene Expression; Gene Expression Profiling; Heart Diseases; Male; Mitochondria, Heart; Myocardium; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Rats; Rats, Inbred SHR; Razoxane; Reverse Transcriptase Polymerase Chain Reaction; Troponin T | 2010 |
The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Topics: Adolescent; Anthracyclines; Cardiovascular Agents; Child; Child, Preschool; Female; Follow-Up Studies; Heart Diseases; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prospective Studies; Razoxane; Survival Rate; Treatment Outcome | 2010 |
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
Topics: Animals; Cardiovascular Agents; Dog Diseases; Dogs; Doxorubicin; Drug Therapy, Combination; Gastrointestinal Diseases; Heart Diseases; Neoplasms; Razoxane | 2010 |
Drug may protect children's hearts from chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Doxorubicin; Female; Heart Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Razoxane; Sex Characteristics | 2010 |
A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.
Topics: Animals; Apoptosis; Autophagy; Benzamides; Cardiotoxins; Heart Diseases; Imatinib Mesylate; Lysosomal-Associated Membrane Protein 2; Male; Muscle Cells; Myocardium; Oligonucleotide Array Sequence Analysis; Oxidation-Reduction; Piperazines; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Razoxane; Sarcomeres; Troponin; Weight Gain | 2011 |
Prevention and treatment of doxorubicin-induced cardiotoxicity by dexrazoxane and schisandrin B in rabbits.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cardiotonic Agents; Cyclooctanes; Doxorubicin; Female; Heart Diseases; Lignans; Male; Malondialdehyde; Natriuretic Peptide, Brain; Polycyclic Compounds; Rabbits; Razoxane; Superoxide Dismutase; Troponin I | 2011 |
[Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Case-Control Studies; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Echocardiography; Female; Heart Diseases; Humans; Infant; Male; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Taxoids; Time Factors; Ventricular Function, Left; Ventricular Function, Right | 2002 |
Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
Topics: Age Factors; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Body Weight; Cell Differentiation; Doxorubicin; Female; Heart Diseases; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Myocardium; Myocytes, Cardiac; Organ Size; Oxidative Stress; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Razoxane; Vesicular Transport Proteins | 2003 |
[Cardioxan: prevention of anthracycline-related cardiotoxicity].
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cardiotonic Agents; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasms; Neoplasms, Experimental; Razoxane; Time Factors | 2004 |
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Topics: Animals; Antibiotics, Antineoplastic; Chelating Agents; Daunorubicin; Heart Diseases; Iron Regulatory Protein 1; Iron-Regulatory Proteins; Male; Rats; Rats, Inbred F344; Razoxane | 2006 |
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Interactions; Heart Diseases; Histones; Humans; Mice; Models, Molecular; Myocytes, Cardiac; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Razoxane; Topoisomerase II Inhibitors | 2007 |
Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
Topics: Adenosine Triphosphate; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Heart Diseases; Humans; Leukemia, Experimental; Male; Mice; Mice, Inbred DBA; Microscopy, Electron; Mitoxantrone; Multiple Myeloma; Myocardium; Rats; Rats, Sprague-Dawley; Razoxane; Sensitivity and Specificity; Tumor Cells, Cultured | 1993 |
Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Topics: Animals; Antibodies, Monoclonal; Antigen-Presenting Cells; Dendritic Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Heart; Heart Diseases; Immunohistochemistry; Incidence; Macrophages; Male; Myocardium; Rats; Rats, Inbred SHR; Razoxane; Severity of Illness Index; T-Lymphocytes | 1993 |
Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane | 1996 |
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
Topics: Adult; Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane | 1996 |
Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Daunorubicin; Drug Evaluation, Preclinical; Heart; Heart Diseases; In Vitro Techniques; Liposomes; Male; Myocardium; Rats; Rats, Sprague-Dawley; Razoxane; Ventricular Function, Left; Ventricular Pressure | 1996 |
Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect.
Topics: Administration, Oral; Animals; Cardiovascular Agents; Doxorubicin; Drug Evaluation, Preclinical; Electroencephalography; Female; Heart Diseases; Myometrium; Piperazines; Rats; Rats, Wistar; Razoxane | 1997 |
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Doxorubicin; Heart Diseases; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Radiation-Protective Agents; Rats; Rats, Inbred SHR; Razoxane | 2000 |
[Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart Conduction System; Heart Diseases; Humans; Razoxane | 2001 |
Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).
Topics: Animals; Antineoplastic Agents; Doxorubicin; gamma-Linolenic Acid; Heart Diseases; Linoleic Acid; Male; Rats; Rats, Sprague-Dawley; Razoxane; Weight Loss | 2001 |
Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Cricetinae; Daunorubicin; Heart Diseases; Liver; Liver Diseases; Male; Mesocricetus; Myocardium; Piperazines; Rats; Razoxane; Stereoisomerism; Time Factors | 1979 |
Reducing the cardiotoxicity of the anthracyclines.
Topics: Antibiotics, Antineoplastic; Biopsy, Needle; Endocardium; Heart Diseases; Heart Failure; Heart Function Tests; Humans; Myocardium; Neoplasms; Razoxane; Risk Factors; Sensitivity and Specificity | 1992 |
The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Topics: Animals; Body Weight; Cardiac Output; Dose-Response Relationship, Drug; Doxorubicin; Heart; Heart Diseases; Heart Failure; Heart Rate; Hemorrhage; Male; Pleural Effusion; Rats; Rats, Inbred Strains; Razoxane; Time Factors | 1992 |
Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Topics: Animals; Blood Cell Count; Body Weight; Combined Modality Therapy; Doxorubicin; Female; Heart Diseases; Hematopoiesis; Hyperthermia, Induced; Kidney Diseases; Nervous System Diseases; Rats; Rats, Inbred F344; Razoxane; Sarcoma, Experimental; Survival Analysis | 1991 |
A drug for prevention of anthracycline-induced cardiac toxicity.
Topics: Adult; Antibiotics, Antineoplastic; Child; Heart Diseases; Humans; Razoxane | 1991 |
Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
Topics: Animals; Doxorubicin; Electrocardiography; Female; Heart Diseases; Myocardial Contraction; Myocardium; Myofibrils; Piperazines; Rats; Razoxane; Vacuoles | 1990 |
ICRF 187.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Heart Diseases; Humans; Piperazines; Razoxane | 1989 |
Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Topics: Animals; Blood Pressure; Body Weight; Doxorubicin; Drug Interactions; Heart Diseases; Heart Rate; Kidney Diseases; Male; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Razoxane; Species Specificity | 1988 |
Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds.
Topics: Acetylcysteine; Animals; Dogs; Doxorubicin; Heart Diseases; Piperazines; Razoxane; Swine; Vitamin E | 1987 |
Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Topics: Animals; Dogs; Doxorubicin; Drug Interactions; Drug Tolerance; Echocardiography; Electrocardiography; Heart; Heart Diseases; Liver; Myocardium; Piperazines; Razoxane | 1988 |
Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Topics: Animals; Blood Cell Count; Body Weight; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Female; Heart Diseases; Hematocrit; Hematologic Diseases; Male; Piperazines; Razoxane | 1987 |